Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 17/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32688927 | 0.86 | ATR (0.66) | ATR | |
| SCHEMBL6701248 | 0.86 | ATR (0.66) | ATR | |
| SCHEMBL29886432 | 0.85 | ATR (0.57) | ATR | |
| SCHEMBL29886145 | 0.85 | ATR (0.57) | ATR | |
| SCHEMBL30785740 | 0.85 | CYP19A1 (0.56) | ATRCYP3A4HSP90AA1HSP90AB1PTK2 | |
| SCHEMBL25735645 | 0.85 | CYP19A1 (0.56) | ATRCYP3A4HSP90AA1HSP90AB1PTK2 | |
| SCHEMBL13137954 | 0.83 | ATR (1.00) | ATR | |
| SCHEMBL2485335 | 0.83 | ATR (0.67) | ATRCYP3A4 | |
| SCHEMBL2503969 | 0.82 | ATR (1.00) | ATR | |
| SCHEMBL2486385 | 0.81 | ATR (0.70) | ATRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077068-A1 | ATP-INDEPENDENT BIOLUMINESCENT REPORTER VARIANTS TO IMPROVE IN VIVO IMAGING | UNIV VIRGINIA PATENT FOUNDATION (US) | 2026-03-19 | — | — | US | disclosed |
| US-20220259574-A1 | ATP-INDEPENDENT BIOLUMINESCENT REPORTER VARIANTS TO IMPROVE IN VIVO IMAGING | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077068-A1 | ATP-INDEPENDENT BIOLUMINESCENT REPORTER VARIANTS TO IMPROVE IN VIVO IMAGING | KCNN2, KCNN1, ATP1B2 | ATR 2600/4885CYP3A4 4128/4885HSP90AA1 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.